A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain

Inclusion Criteria: * Malignant melanoma (including melanoma of unknown primary site, recurrent and pretreated systemic melanoma and/or melanoma with parenchymal CNS metastases) with leptomeningeal metastasis as demonstrated by a positive CSF (cerebrospinal liquor) cytology AND/OR by the presence of characteristic signs and symptoms of leptomeningeal metastasis supported by an MRI scan indicating the presence of meningeal tumour * CSF flow abnormalities must be excluded * Males or females ≥ 18 years of age * Karnofsky Performance Status \> 50% * Adequate organ function (adequate bone marrow reserve, adequate liver function, adequate renal function. adequate blood clotting) Exclusion Criteria: * Unresected parenchymal brain metastases with a diameter \> 3 cm * Prior non melanoma malignancy (unless adequately treated carcinoma in situ of the cervix or non melanoma skin cancer) * Prior intrathecal chemotherapy * Prior treatment with systemic cytarabine or nitrosureas * The patient ist pregnant or breast feeding * Severe, active co-morbidities